The Gastrointestinal Stromal Tumor: the first systematic, comprehensive and professional journal for gastrointestinal stromal tumor

GIST Editorial Office


Gastrointestinal stromal tumors (GISTs) originate from mesenchymal tissue and have a potential malignant tendency. The incidence rate is 1–2/10 million. These tumors occur in the entire digestive tract, and most commonly in the stomach (approximately 60%), and the parameters of immunohistochemical expression are CD34, CD117 and Dog 1 (1-3). Since the mutation of c-kit gene in GIST was discovered by Japanese scholars in 1998 (4) and the first case of tyrosine kinase inhibitors in the treatment of metastatic GIST occurred in 2001 (5), GIST has attracted the attention of doctors and gradually become a model of targeted therapy (6).